Company Analysis
Sign in

Matinas BioPharma Holdings, Inc. (MTNB)

NYSE: MTNB · Pharmaceutical Preparations · Bedminster, NJ · filing with the SEC since 2013
Full chart Alerts Compare
Grade4.4
◀ Past 4.6● Present 2.9▶ Future 5.6
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Matinas BioPharma Holdings, Inc.

Nine metrics read from its own filings, by tense
Headline grade
4.4/10
◀ Past4.625% of the headline
● Present2.935% of the headline
▶ Future5.640% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.6/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
2.1/10

Has it survived what it has been through?

6 warning events since 2017; the latest 2026-09-04.

weight 22% of this tense · 21st percentile among 497 sector filers · read for itself

From the record

Matinas BioPharma Holdings, Inc.'s filings since 2017 show 6 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 5 times, the latest 2026-09-04); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2025-03-31) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
4.2/10

What has it actually done, year after year?

+55.7% a year over 6 filed years; profitable in 0 of 6.

weight 45% of this tense · 42nd percentile among 323 sector filers · read for its customers

From the record

Matinas BioPharma Holdings, Inc.'s 6 filed years say what it did: revenue went from $120 thousand in fiscal 2018 to $1 million in fiscal 2023, up 55.7% a year; it rose in 2 of 5 years; the deepest fall was 79% from fiscal 2020 to fiscal 2021; net income was positive in 0 of 6 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span55.7%top 22% of its family
  • the share of years revenue rosebottom 24% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak79.2%bottom 40% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
6.9/10

How has it treated the people who own it?

SI estimate 6.9/10, confidence 35 of 100 (one part).

weight 33% of this tense · 69th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 31% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Matinas BioPharma Holdings, Inc.'s shareholder treatment is put at 6.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 31% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

2.9/1035% of the headline grade · 3 of 3 filed

Financial health

as filed
4.1/10

Is it financially healthy right now?

ROE -214%: lost 214¢ per shareholder dollar. Leverage 33%: owes 33¢ per asset dollar.

weight 45% of this tense · 41st percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Matinas BioPharma Holdings, Inc. lost about 214 cents for every dollar of shareholders' money. Leverage: it owed about 33 cents per dollar of assets, and net share issuance: its share count grew 12.5% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 49% of its family
  • return on equitybottom 14% of its family
  • the share count against the year beforetop 42% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
4.4/10

How strong is its position in its industry?

bottom 44% of 315 in its family; net margin -2093.2%.

weight 22% of this tense · 44th percentile among 315 sector filers · read for its customers

From the record

Matinas BioPharma Holdings, Inc.'s standing among 315 graded names in its industry family: revenue of $1 million in fiscal 2023 ranks in the bottom 23% by size; a net margin of -2093.2% ranks in the bottom 23%; revenue growth of 90.7% a year over the last 3 filed years ranks in the top 15% (its annual reports).

What it rests on

  • revenue against the family$1.1Mbottom 23% of its family
  • net margin-2093.2%bottom 23% of its family
  • three-year revenue growth90.7%top 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
0.3/10

What are the people in charge doing?

bottom 3% of 315 in its family for leadership.

weight 33% of this tense · 3rd percentile among 315 sector filers · read for its shareholders

From the record

Matinas BioPharma Holdings, Inc.'s leadership, from its insiders' filings and its current reports: no one files under a chief executive's title, so that part is not read; the 4 officers and directors filing in the last fifteen months have been on the record a median of 1.7 years (bottom 6%); 15 officer or director changes were reported on Form 8-K since 2023-11-13, against the 4 people in charge now (bottom 1%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge15 in three years among 4 peoplebottom 1% of its family
  • the median years the people in charge have filed1.7 yearsbottom 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

5.6/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

SI estimate
7.0/10

How much room does it have to grow?

SI estimate 7.0/10, confidence 35 of 100 (one part).

weight 33% of this tense · 70th percentile among 479 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, cash less debt against assets, which ranks in the top 30% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read
The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned
one part: cash less debt against assets, the one part on file, ranked among 479 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Matinas BioPharma Holdings, Inc.'s room to expand is put at 7.0 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 30% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed
5.0/10

What could actually drive growth from here?

bottom 49% of 306 in its family for growth drivers.

weight 45% of this tense · 49th percentile among 306 sector filers · read for its customers

From the record

Matinas BioPharma Holdings, Inc.'s growth drivers, from the filed years to fiscal 2023: revenue grew 90.7% a year over the last three filed years against 55.7% over all 6, speeding up (top 12% of its family); the newest year grew -65.6% (bottom 11%); research spending grew -82.8% a year (bottom 1%); capital spending grew 236.2% a year (top 2%) (its annual reports). Matinas BioPharma Holdings, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+34.9 points a yeartop 12% of its family
  • the newest year's revenue growth-65.6%bottom 11% of its family
  • three-year growth of research spending-82.8%bottom 1% of its family
  • three-year growth of capital spending236.2%top 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
4.8/10

Did its newest year beat what its own record pointed to?

bottom 47% of 233 in its family for expectations against reality.

weight 22% of this tense · 47th percentile among 233 sector filers · read for its shareholders

From the record

Matinas BioPharma Holdings, Inc.'s newest year against its own record: revenue of $1 million in fiscal 2023 came in 92.3% below the $14 million its prior three years' pace pointed to (bottom 6% of its family); net income of $23 million against a prior three-year average of $22 million (bottom 41%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 4%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace-92.3%bottom 6% of its family
  • net income against the prior three years' average-3%bottom 41% of its family
  • net margin against its prior averageup more than 100 pointstop 4% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton MTNB · research, not advice